Phase 2 Trial of a Novel Peptide Vaccine (PEP-CMV) Targeting CMV Antigen for Newly Diagnosed Pediatric High-grade Glioma and Diffuse Intrinsic Pontine Glioma and Recurrent Medulloblastoma
Latest Information Update: 26 Sep 2024
At a glance
- Drugs PEPIDH1M (Primary) ; Diphtheria-tetanus vaccine; Montanide ISA-51; Temozolomide
- Indications Anaplastic astrocytoma; Diffuse intrinsic pontine glioma; Glioblastoma; Glioma; Medulloblastoma
- Focus Therapeutic Use
- 01 Aug 2024 Status changed from not yet recruiting to recruiting.
- 11 Jul 2024 Planned initiation date changed from 15 Jun 2024 to 30 Jul 2024.
- 10 May 2024 Planned End Date changed from 15 Apr 2030 to 15 Jun 2030.